Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospectiveï¼ŒOpen-label, Single-arm Study.
The is a phase 2, single-arm, open-label clinical study assessing the efficacy and safety of hetrombopag to increase platelet count in lower-risk MDS patients with thrombocytopenia.
Myelodysplastic Syndromes
DRUG: Hetrombopag
Platelet response, proportion of patients achieving platelet responses at week 24, 24 weeks
Overall response rate, Patients will be assessed for response according to the IWG criteria., 24 weeks|Proportion of patients with platelet response during treatment, Improvement in platelet counts by 24 weeks of therapy, 24 weeks|Incidence and severity of bleeding events according to the WHO Bleeding Scale, The severity of bleeding symptoms was graded according to the World Health Organization (WHO) bleeding scale (grade 0: no bleeding; grade 1: petechiae; grade 2: mild blood loss; grade 3, gross blood loss; grade 4: debilitating blood loss)., 28 weeks|Adverse events, Adverse events were recorded and graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, 28 weeks
The is a phase 2, single-arm, open-label clinical study assessing the efficacy and safety of hetrombopag to increase platelet count in patients with very low, low, or intermediate risk myelodysplastic syndromes(MDS) according to the revised International Prognostic Scoring System (IPSS-R) with thrombocytopenia. The primary endpoint was proportion of patients achieving platelet response at week 24.